{'fraction_non_alphanumeric': 0.041428571428571426, 'fraction_numerical': 0.014285714285714285, 'mean_word_length': 6.302083333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
B‐Lymphocytes Activated by CD40 Ligand Induce an Antigen‐Specific Anti‐Tumour Immune Response by Direct and Indirect Activation of CD8+ T‐cells

In this report, we describe the ability of CD40‐ligand (CD40L)‐activated, antigen‐loaded B‐cells to initiate antigen‐specific anti‐tumour immune responses in vivo. Mice immunized by means of intravenous administration of CD40L‐activated B‐cells loaded with an MHC class‐I‐binding peptide, and challenged with a tumour cell line expressing the same class‐I epitope, showed a marked delay in tumour growth, compared to non‐immunized controls or to mice receiving either freshly isolated B‐cells or B‐cells activated with lipopolysaccharide or interleukin‐4.